Whistling Past the Graveyard: The Problem with the Per Se Legality Treatment of Pay-For-Delay Settlements
Michael Kades, Nov 01, 2009
Arguably, the most important debate in antitrust jurisprudence involves pay-for-delay patent settlements in which the brand company pays the generic to stay out of the market. As a matter of economics, it will generally be most profitable if the brand and the generic firm avoid the possibility of competition and share the resulting monopoly profits; however, such settlements will reduce competition and increase the costs of drugs. If pay-for-delay settlements are legal, parties will enter them to the detriment of consumers. Current cases, in particular the Tamoxifen and Ciprofloxacin decisions, however, have gone a long way towards adopting just such a standard, a standard that is already having an effect. By adopting an approach without regard to its implications or erroneously suggesting that pay for delay settlements are an ineffective way to delay competition, courts are essentially whistling past the graveyard.
Featured News
Croatia Competition Authority Approves HPB Acquisition of Croatia Banka
Jul 19, 2026 by
CPI
Democratic Lawmakers Urge DOJ to Closely Examine Fox-Roku Merger
Jul 19, 2026 by
CPI
US Judge Clears Path for Broad Beef Antitrust Class Actions Against Major Meatpackers
Jul 19, 2026 by
CPI
India’s Competition Regulator Dismisses Antitrust Complaint Against Reliance Jio and 4,500 Firms
Jul 19, 2026 by
CPI
Apple Opens Early Settlement Discussions With DOJ
Jul 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Agentic AI & Antitrust
Jul 16, 2026 by
CPI
AI Agents and Collusion: The Two Faces of Agentic AI
Jul 16, 2026 by
Giovanna Massarotto
Agentic AI’s Regulatory Conundrum
Jul 16, 2026 by
Anant Raut
Inter-AI-Agent Competition
Jul 16, 2026 by
Stefan Thomas
Navigating the Increasing Regulatory Scrutiny of AI-Pricing Tools: Competition and Other Emerging Risks
Jul 16, 2026 by
Mark Krotoski & Vinny Sidhu